Statement: At least 1 participant in each cohort of the primary trial showed signs of poor liver function.
Primary_evidence: Adverse Events 1:   Total: 4/109 (3.67%)   Anaemia * 0/109 (0.00%)   Haemolytic uraemic syndrome * 0/109 (0.00%)   Leukopenia * 0/109 (0.00%)   Cardiac failure * 0/109 (0.00%)   Pyrexia * 1/109 (0.92%)   Hepatic function abnormal * 1/109 (0.92%)   Arthritis bacterial * 0/109 (0.00%)   Lung infection * 0/109 (0.00%)   Haemoglobin decreased * 1/109 (0.92%)   Neutrophil count decreased * 0/109 (0.00%) Adverse Events 2:   Total: 9/110 (8.18%)   Anaemia * 1/110 (0.91%)   Haemolytic uraemic syndrome * 0/110 (0.00%)   Leukopenia * 0/110 (0.00%)   Cardiac failure * 1/110 (0.91%)   Pyrexia * 2/110 (1.82%)   Hepatic function abnormal * 0/110 (0.00%)   Arthritis bacterial * 2/110 (1.82%)   Lung infection * 0/110 (0.00%)   Haemoglobin decreased * 1/110 (0.91%)   Neutrophil count decreased * 0/110 (0.00%)